Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Dave Gore who wrote (1557)	2/11/1999 9:40:00 PM
From: Anthony@Pacific	Read Replies (3) \| Respond to of 2135

NCI<---NON PROFIT " feel good group" Bristol Meyers<-------FOR-PROFIT " CAN it make money?....NO! ...OK Can IT!!!"

To: Dave Gore who wrote (1557)	2/11/1999 9:45:00 PM
From: tommysdad	Read Replies (1) \| Respond to of 2135

Sorry, you're totally missing the point. BMY didn't say AS didn't work. They said they couldn't make it reproducibly in sufficient quantity to make it a drug. And the recent news about from the NCI is about ES, not AS. And, still, the NCI has only gotten it to work in Folkman's lab, they haven't transferred the technology to their own lab yet. So we have a couple of interesting proteins that seem to work but only under strictly controlled conditions and no one has yet made enough of either protein for clinical trials, let alone sales. So, anyone buying this stock is betting that: (a) ENMD and/or Covance will be able to prepare AS and/or ES in sufficient quantities for clinical trials and eventually sales. (b) Material prepared in this way will be of sufficient quality to be as active as the very small amounts tested in the mice. (c) The dramatic results obtained in Folkman's lab will be reproduced somewhere, sometime (most experiments to date get good results, but not as dramatic as those described in the NY Times article that started this debacle). (d) What worked in mice will work in humans. (Oh, and don't forget the reproducibility angle. Clinicals will be run at a number of different sites throughout the country -- you can't ask all the patients to fly to Children's Hospital to get the injections.) (e) ENMD has the bucks to develop AS/ES, or can find another partner. (f) Any one or several of the dozen or so other anti-angiogenesis drugs don't make it to market first -- using the much preferred oral route of administration. Don't get me wrong, I'm not questioning the results obtained in Folkman's lab. But this stuff is so far away from being a drug(s) that generates revenue that the market cap ENMD has today is way ahead of itself. I believe that 90% of the people buying this stock today have no idea of what they are buying. Good luck. There will be plenty of "buying opportunities" before the above questions are answered and ENMD starts generating revenue . . . . . . of course, that hasn't stopped the Internet stocks from doing OK.